What is uBriGene Biosciences?
uBriGene Biosciences is dedicated to advancing innovation and expediting the journey of biologics development from initial concept through to commercialization. The company focuses on delivering superior quality products and services to its clientele, aiming to optimize both time and cost efficiencies within the development lifecycle. This commitment positions uBriGene as a key player in streamlining the complex process of bringing new biological therapies to market.
How much funding has uBriGene Biosciences raised?
uBriGene Biosciences has raised a total of $68M across 3 funding rounds:
Series A
$19M
Series B
$29M
Series C
$20M
Series A (2020): $19M, investors not publicly disclosed
Series B (2021): $29M, investors not publicly disclosed
Series C (2023): $20M, investors not publicly disclosed
What's next for uBriGene Biosciences?
The recent major strategic investment signifies a pivotal moment for uBriGene Biosciences, likely enabling the company to scale its operations, expand its research and development capabilities, and potentially broaden its market reach. This capital infusion is expected to accelerate the company's mission to enhance efficiency in biologics development, positioning it for further growth and impact within the life sciences industry. Future endeavors may include strategic partnerships, further technological advancements, and expansion into new therapeutic areas.
See full uBriGene Biosciences company page
